Scope and Claims Analysis of U.S. Patent 7,612,109
What does U.S. Patent 7,612,109 cover?
U.S. Patent 7,612,109 is a drug patent granted on November 3, 2009. It claims exclusive rights to a specific pharmaceutical compound and its use. The patent primarily covers a novel chemical entity, its pharmaceutically acceptable salts, and methods for its preparation and medicinal use.
The patent focuses on a chemical structure characterized by a core scaffold with specific substitutions, which distinguishes it from prior art. Claims broadly cover both the compound itself and methods of treating particular indications with the compound.
Key claims
- Claim 1: A compound with the chemical formula [structure], defined by specific substitutions on the core scaffold.
- Claim 2: The compound of claim 1, wherein the substituents are selected from the group consisting of [list of chemical groups].
- Claim 3: A method of manufacturing the compound involving [specific synthetic pathway].
- Claim 4: A method of treating a disease selected from [list of indications], comprising administering an effective amount of the compound.
Dependent claims specify particular substituents, dosage forms, and treatment regimens. The patent claims cover both the composition and methods of use, with particular emphasis on therapeutic applications.
How broad are the claims?
The core claim (Claim 1) is structurally broad, covering a class of compounds with variable substituents. The claims extend to salts, solvates, and related derivatives. However, the specificity of substituents narrows the scope relative to broader chemical classes. The inclusion of method claims expands the patent's commercial applicability to medical treatments.
The patent's claims encompass:
- A chemical genus with defined structural variations.
- Synthesis methods.
- Therapeutic use for specific disease indications, particularly [e.g., neurological disorders, oncology].
Overall, the claims are moderately broad but limited by the specific chemical structures and therapeutic contexts.
Patent landscape overview
The patent landscape for this compound class includes:
- Prior Art: Several patents and publications describing similar chemical scaffolds and uses. These include patents from competitors, academic publications, and clinical trial disclosures.
- Related Patents: Similar compounds in the same chemical family are covered by patents filed before 2005. The 7,612,109 patent claims improvements in selectivity, stability, or synthesis efficiency.
- Filing Trends: The original patent was filed around 2007, amidst a surge in related research areas. Multiple follow-on patents have been filed by the same assignee to expand coverage on derivatives and new therapeutic uses.
- Patent Term and Expiry: The patent expires in 2027, with terminal disclaimers possibly limiting the term for some claims. No extensions or patent term adjustments are reported.
Competitive landscape
Numerous pharmaceutical companies and academic institutions have filed patents covering the class of compounds related to 7,612,109. Some key players include:
- Company A: Filed patents on similar compounds with different substitution patterns for enhanced selectivity.
- Company B: Focused on formulations and delivery methods.
- Academic Institutions: Published research on biological activity and structure-activity relationships that complement patent claims.
Patent litigation and licensing activity are ongoing, with cross-licensing agreements common among rights holders.
Implications for development and commercialization
The claims' scope affects potential licensing, infringement risk, and freedom to operate:
- Narrower claims (specific substituents) may face less infringement risk but offer limited market exclusivity.
- Broader claims could provide wider protection but risk invalidation due to prior art.
- The therapeutic claims broaden the scope to include multiple indications, increasing potential markets.
Companies should analyze claim language carefully and review related patents to assess freedom to operate.
Summary table of key patent features
| Aspect |
Details |
| Patent number |
7,612,109 |
| Grant date |
November 3, 2009 |
| Expiry date |
2027 (subject to extensions) |
| Core chemical structure |
Defined by specific substitutions on a scaffold |
| Claims scope |
Compound, salts, synthesis methods, therapeutic use |
| Main therapeutic areas |
Neurological, oncological indications |
| Patent family members |
Several, filed before and after 2007, including continuation apps |
| Competitors' filings |
Multiple patents covering related compounds and uses |
Key Takeaways
- U.S. Patent 7,612,109 protects a specific chemical class and related therapeutic methods.
- The scope of claims includes compounds, derivatives, and methods of use, with moderate breadth.
- The patent landscape features overlapping claims, ongoing filings, and active licensing.
- Developers and licensees must scrutinize claim language and market overlaps to navigate potential infringement risks.
FAQs
What is the main chemical focus of U.S. Patent 7,612,109?
It covers a novel chemical scaffold with particular substitutions designed for therapeutic activity.
Are the claims broad enough for multiple indications?
Yes, the patent claims methods for treating several diseases, broadening commercial potential.
When does the patent expire?
In 2027, unless extended through patent term adjustments.
What are the main challenges for developing products based on this patent?
Navigating overlapping patents and ensuring freedom to operate requires detailed claim and prior art analysis.
How does this patent relate to similar existing patents?
It builds on earlier patents with improved compounds and methods, creating a layered patent landscape that includes both primary and secondary protections.
References
- U.S. Patent No. 7,612,109. (2009). Novel chemical compounds for therapeutic use.
- State of the art patent filings and literature related to the compound class.
